Active Clinical Trials

April 27, 2021

Trial Spotlight: Search for patients intensifies with the opening of a new NCI-MATCH treatment arm

In this interview, Dr. Peter O'Dwyer urges physicians, sites, and testing laboratories to redouble efforts to locate patients for 12 open arms
March 31, 2021
Doctor patient skin exam

Now Enrolling: EA6194 for Operable Melanoma

This phase II study, led by Dr. Ahmad Tarhini, is testing neoadjuvant treatment with pembrolizumab alone versus pembrolizumab and an investigational drug called CMP-001
March 31, 2021
Doctor listening to patient's lungs

Now Enrolling: PrE0506 / DREAM3R for Patients with Malignant Pleural Mesothelioma

This phase III study, led by Drs. Patrick Forde and Anna Nowak, is evaluating durvalumab immunotherapy during and after standard chemotherapy versus chemotherapy alone
March 31, 2021
Female doctor consulting with older male patient

Trial Spotlight: Amer Zeidan on the BLAST MRD CML 1 Study for Chronic Myeloid Leukemia

The EA9171 phase II trial aims to determine if adding pembrolizumab immunotherapy to standard-of-care TKI therapy helps more patients achieve undetectable minimal residual disease and allows them to discontinue TKI therapy
February 25, 2021
Older patient throat exam

Now Enrolling: EA3191 for Head and Neck Squamous Cell Carcinoma

This three-arm phase II study, led by Dr. Dan Zandberg, is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
February 25, 2021
Patient and doctor talking in office

Trial Spotlight: Shaji Kumar on the EQUATE Study for Newly Diagnosed Multiple Myeloma

The randomized EAA181 phase III trial seeks to determine whether there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
January 25, 2021
Doctor with male patient

Now Enrolling: EA8183 / ERADICATE for Patients with Localized Prostate Cancer

This phase III study, led by Dr. Alicia Morgans, is exploring a new treatment option for patients with prostate cancer with high-risk features
January 25, 2021
Woman patient speaking with doctor

Now Enrolling: EA2197 / OPT-IN for Gallbladder Cancer

This phase II/III study, led by Dr. Shishir Maithel, is assessing the role of neoadjuvant therapy for patients with incidental gallbladder cancer
January 25, 2021
PrECOG logo

Trial Spotlight: Jonathan Cohen, MD on Trial PrE0404 for Relapsed/Refractory Mantle Cell Lymphoma

This phase I/II study, led by Dr. Jonathon Cohen, is evaluating the combination of ibrutinib and the oral proteasome inhibitor ixazomib in patients with relapsed/refractory mantle cell lymphoma
December 14, 2020
Clipboard and laptop

Now Enrolling: ECOG-ACRIN Opened Five New Trials in October

The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
December 14, 2020
Man holding throat

Reopened Trial: Jennifer Eads, MD on Study EA2174 for Esophageal and Gastroesophageal Cancer

EA2174 will evaluate the role of perioperative immunotherapy for patients with esophageal or gastroesophageal junction adenocarcinoma
October 19, 2020
TMIST accrual bar graph

TMIST Breast Cancer Screening Trial Rebounds from COVID-19 Shutdown of Cancer Screenings

October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance